Can Preoperative Haematological Parameters Predict Pathology Results in Patients Undergoing Open Prostatectomy Due to Benign Prostatic Hyperplasia? A Retrospective Study

Objective: Although the incidence of incidental prostate cancer (IPCa) has decreased in patients undergoing open prostatectomy with the increasing use of prostate-specific antigen (PSA), cases of IPCa are still reported. This study aimed to investigate the rate of IPCa in our patients who underwent open prostatectomy and to find the relationship between haematological parameters and pathology results. Materials and Methods: Data of patients who underwent open prostatectomy in our urology clinic between January 2014 and December 2019 were retrospectively investigated. Patient age, preoperative PSA level, prostate volume, post-void residual urine volume, history of urethral catheterisation, presence of accompanying bladder stones, pathology results of prostate biopsy, post-operative pathology results, haematological parameters, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were evaluated. Results: A total of 83 male patients were included in the study. The mean patient age was 68.89±6.72 years. The mean preoperative PSA value was 7.46±6.23 ng/mL. Benign prostatic hyperplasia was detected in the post-operative pathology results of all patients; however, prostate adenocarcinoma was found in six (7.2%) and chronic prostatitis accompanied with benign prostatic hyperplasia was detected in 46 (55.4%) patients. PLR and NLR were higher in patients with IPCa than in patients without IPCa. The difference was statistically significant in terms of PLR (p=0.010). By contrast, the mean lymphocyte count was significantly lower in patients with IPCa than in those without IPCa (p=0.009). Conclusion: This study showed that the rate of IPCa in our clinic was similar to that in literature. Results suggest that evaluation of preoperative haematological parameters in patients who underwent open prostatectomy may guide urologists and pathologists in predicting pathological conditions.

Benign Prostat Hiperplazisi Nedeniyle Açık Prostatektomi Uygulanan Hastalarda Preoperatif Hematolojik Parametreler Patoloji Sonuçlarını Öngörebilir mi? Retrospektif Bir Çalışma

Amaç: Prostat spesifik antijen (PSA) kullanım sıklığının artması ile açık prostatektomi uygulanan hastalarda insidental prostat kanseri (İPK) görülme sıklığı azalmış olsa da devam etmektedir. Bu çalışmanın amacı, açık prostatektomi uygulanan hastalarımızda İPK oranı ve hematolojik parametreler ile patoloji sonuçları arasında bir ilişki olup olmadığını araştırmaktır. Gereç ve Yöntemler: Ocak 2014 - Aralık 2019 tarihleri arasında üroloji kliniğimizde açık prostatektomi geçiren hastaların verileri geriye dönük olarak incelendi. Hastaların yaşı, ameliyat öncesi PSA değeri, prostat hacmi, işeme sonrası rezidüel idrar miktarı, üretral kateterizasyon öyküsü, eşlik eden mesane taşı varlığı, prostat biyopsisinin patoloji sonuçları, post-operatif patoloji sonuçları, hematolojik parametreler ve nötrofil-lenfosit oranı (NLO) ve trombosit-lenfosit oranı (PLO) değerlendirildi. Bulgular: Çalışmaya toplam 83 erkek hasta dahil edildi. Hastaların ortalama yaşı 68,89±6,72 yıldı. Preoperatif ortalama PSA değeri 7,46±6,23 ng/mL idi. Tüm hastaların post-operatif patoloji sonuçlarında benign prostat hiperplazisi saptanırken, 6 hastada (%7,2) prostat adenokarsinomu ve 46 hastada (%55,4) kronik prostatitin benign prostat hiperplazisine eşlik ettiği görüldü. İPK’li hastalarda, İPK olmayan hastalara göre PLO ve NLO’nun daha yüksek olduğu görüldü. Bu yükseklik PLO açısından istatistiksel olarak anlamlıydı (p=0.010). Öte yandan, ortalama lenfosit sayısı İPK olan hastalarda İPK olmayan hastalara göre anlamlı olarak daha düşüktü (p=0,009). Sonuç: Bu çalışma, kliniğimizde İPK oranının literatürdekine benzer olduğunu göstermiştir. Ayrıca sonuçlar, açık prostatektomi uygulanan hastalarda preoperatif hematolojik parametrelerin değerlendirilmesinin ürologlar ve patologlar için patoloji sonuçlarını tahmin etmede yol gösterici olabileceğini düşündürmektedir.

PDF

___

1. McVary KT. BPH: epidemiology and comorbidities. Am J Manag Care 2006; 12: 122-8.

2. Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms including Benign Prostatic Obstruction. Eur Urol 2015; 67: 1099-109.

3. Pariser JJ, Packiam VT, Adamsky MA, Bales GT. Trends in Simple Prostatectomy for Benign Prostatic Hyperplasia. Curr Urol Rep 2016; 17: 57.

4. Otto B, Barbieri C, Lee R, Te AE, Kaplan SA, Robinson B, et al. Incidental prostate cancer in transurethral resection of the prostate specimens in the modern era. Adv Urol 2014; 2014: 627290.

5. Capitanio U, Cheng L, Lopez-Beltran A, Scarpelli M, Freschi M, Montorsi F, et al. The importance of interaction between urologists and pathologists in incidental prostate cancer management. Eur Urol 2011; 60: 75-7.

6. Acharya AB, Shetty IP, Jain S, Padakannaya I, Acharya S, Shettar L, et al. Neutrophil-to-lymphocyte ratio and plateletto-lymphocyte ratio in chronic periodontitis before and after nonsurgical therapy. J Indian Soc Periodontol 2019; 23: 419-23.

7. Meshaal MS, Nagi A, Eldamaty A, Elnaggar W, Gaber M, Rizk H. Neutrophil-to-lymphocyte ratio (NLR) and platelet-tolymphocyte ratio (PLR) as independent predictors of outcome in infective endocarditis (IE). Egypt Heart J 2019; 71: 13.

8. Adhyatma KP, Prapiska FF, Siregar GP, Warli SM. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio. Open Access Maced J Med Sci 2019; 7: 1628-30.

9. Otsubo S, Yokomizo A, Mochida O, Shiota M, Tatsugami K, Inokuchi J, et al. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate. World J Urol 2015; 33: 329-33.

10. Güner E, Şeker KG. Incidental Prostate Cancer and Its Characteristics in Patients Undergoing Open Prostatectomy Due to Benign Prostatic Hyperplasia. Med J Bakirkoy 2019; 15: 87-90.

11. Schaeffer AJ, Landis JR, Knauss JS, Propert KJ, Alexander RB, Litwin MS, et al. Demographic and clinical characteristics of men with chronic prostatitis: the national institutes of health chronic prostatitis cohort study. J Urol 2002; 168: 593-8.

12. Qin B, Ma N, Tang Q, Wei T, Yang M, Fu H, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients. Mod Rheumatol 2016; 26: 372-6.

13. Adhyatma KP, Prapiska FF, Siregar GP, Warli SM. Systemic Inflammatory Response in Predicting Prostate Cancer: The Diagnostic Value of Neutrophil-To-Lymphocyte Ratio. Open Access Maced J Med Sci 2019; 7: 1628-30.

14. Cihan YB, Arslan A, Ergul MA. Subtypes of white blood cells in patients with prostate cancer or benign prostatic hyperplasia and healthy individuals. Asian Pac J Cancer Prev 2013; 14: 4779- 83.

15. Sun Z, Ju Y, Han F, Sun X, Wang F. Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer. J Clin Lab Anal 2018; 32: e22277.

16. Gokce MI, Hamidi N, Suer E, Tangal S, Huseynov A, Ibiş A. Evaluation of neutrophil-to-lymphocyte ratio prior to prostate biopsy to predict biopsy histology: Results of 1836 patients. Can Urol Assoc J 2015; 9: 761-5.

17. Li F, Hu H, Gu S, Chen X, Sun Q. Platelet to lymphocyte ratio plays an important role in prostate cancer’s diagnosis and prognosis. Int J Clin Exp Med 2015; 8: 11746-51.

18. Yuksel OH, Urkmez A, Akan S, Yldirim C, Verit A. Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer. Asian Pac J Cancer Prev 2015; 16: 6407-12.

19. Zahorec R. Ratio of neutrophil to lymphocyte counts--rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy 2001; 102: 5-14.